788 results about "Metastasis" patented technology

Presented herein are systems and methods that provide for improved computer aided display and analysis of nuclear medicine images. In particular, in certain embodiments, the systems and methods described herein provide improvements to several image processing steps used for automated analysis of bone scan images for assessing cancer status of a patient. For example, improved approaches for image segmentation, hotspot detection, automated classification of hotspots as representing metastases, and computation of risk indices such as bone scan index (BSI) values are provided.

The invention provides a thyroid cancer auxiliary diagnosis and metastasis risk prediction method based on deep learning, and relates to the technical field of artificial intelligence auxiliary medical treatment, and the method comprises the steps: extracting ultrasonic image multi-scale features through a self-adaptive neural architecture search network, combining clinical examination data, fusing diagnosis and treatment knowledge through a neural symbol inference device, and carrying out the prediction of the metastasis risk. Generating a knowledge enhancement feature map; constructing a feature propagation field by using a dynamic neural field network, solving a dynamic evolution equation, and generating a spatial-temporal feature field representing the dynamic change of focus features; constructing a tumor diffusion kinetic model by using an implicit neural representation network and a nerve ordinary differential equation network, calculating a transition probability based on an optimal transmission algorithm, solving an optimal control equation, and outputting a metastasis risk prediction result of each organ; the thyroid cancer diagnosis accuracy and metastasis risk prediction reliability can be effectively improved, and doctors can be assisted in accurate diagnosis and treatment.

Provided herein are systems, compositions, and methods for generating immunogenic peptides or epitopes from tumor associated antigens (e.g., in vivo or ex vivo). Polynucleotides (e.g., genes) encoding the tumor associated antigens may be edited at selected target sites by nucleobase editors comprising a catalytically-inactive Cas9 and a cytosine deaminase, leading to the expression of heteroclitic or cryptic peptides that are more immunogenic than the native peptide derived from the tumor associated antigens. The heteroclitic or cryptic peptide elicit strong tumor-specific immune response (e.g., T-cell response or B-cell response), which inhibits tumor growth and metastasis.

The present invention relates to a use of a novel compound for the prevention, alleviation, or treatment of breast cancer, the novel compound of the present invention not only being capable of notably inhibiting the growth, proliferation, migration, carcinogenicity, and metastasis of breast cancer cells, but also being capable of simultaneously inhibiting ANO1 and EGFR in breast cancer cells, thereby being capable of exhibiting a stronger anticancer effect through the dual inhibition of the two proteins. In addition, the compound, when used in combination with an anticancer agent, may further enhance the efficacy of the anticancer agent, and may inhibit the resistance of the cancer. Thus, the compound itself may be used as a dual-target anticancer agent against ANO1 and EGFR, and may also be utilized as a combined preparation of an anticancer agent, and thus is expected to be utilized in various ways in the field of breast cancer prevention and treatment.

The invention discloses a tumor stem cell targeting virus-like drug carrier as well as a preparation method and application thereof. The drug carrier provided by the invention can improve the cell uptake efficiency by simulating the physical surface characteristics of a biological system, and can directly target tumor stem cells. Besides, the drug carrier has targeting property, so that healthy tissues can be protected, the side effects of the loaded drug such as PTC209 in high-dose independent use are obviously reduced, the reaction to tumor stem cells is effectively enhanced, tumor proliferation and metastasis are inhibited, and the drug resistance of drug combination such as cis-platinum is reduced.

The present invention relates to a use of a novel compound for the prevention, amelioration, or treatment of head and neck cancer. The novel compound of the present invention not only significantly inhibits the growth, proliferation, migration, and metastasis of head and neck cancer cells, but also simultaneously inhibits ANO1 and EGFR in head and neck cancer cells, thereby exerting a stronger anticancer effect through dual inhibition against these two proteins. In addition, when used in combination with an anticancer agent or the like, the compound can enhance the efficacy of the anticancer drugs and suppress drug resistance. Accordingly, the compound can be used as a dual-target anticancer agent for ANO1 and EGFR on its own, or as a combination agent with anticancer drugs, and is expected to be widely applicable in the field of prevention and treatment of head and neck cancer.

The invention relates to the technical field of biomedicine, in particular to a method for constructing a plasma ctDNA organ distribution characteristic spectrum of advanced colorectal cancer. The method comprises the following steps: collecting a peripheral blood sample at multiple time points, separating plasma by adopting a double-centrifugal method, and extracting circulating tumor DNA (Deoxyribose Nucleic Acid); carrying out whole exome sequencing based on ctDNA to obtain genome variation information and calculating variation allele frequency, and synchronously detecting the expression quantity of immune-related proteins by adopting an Olink proteomics technology; integrating the genome data, the protein expression data and the clinical pathological features, and constructing a multi-dimensional feature data matrix; and taking the organ metastasis condition confirmed by iconography as a supervision label, training a model by applying a machine learning algorithm, screening key prediction factors, constructing a quantitative prediction model, and finally generating a visual organ metastasis tendency prediction map. According to the method, early and accurate prediction of the advanced colorectal cancer organ metastasis tendency is realized through multi-omics data collaborative analysis and machine learning modeling.

The invention relates to a hepatocellular carcinoma gene knockout target library based on multiple omics and a screening method of the hepatocellular carcinoma gene knockout target library, and the gene knockout target library for precise treatment of hepatocellular carcinoma is finally obtained through data collection and integration, data screening and target verification in sequence. According to the invention, through multi-omics data integration and bioinformatics analysis, key driving genes of hepatocellular carcinoma are systematically screened, and the important effects of the genes in occurrence, development, metastasis, drug resistance and immune escape of hepatocellular carcinoma are disclosed; the genes not only deepen the understanding of the hepatocellular carcinoma molecular mechanism, but also provide important theoretical basis and potential intervention targets for the development of targeted therapy and personalized therapy strategies.

The invention discloses an exosome engineered targeted drug delivery system and a preparation method and application thereof, and belongs to the field of biomedices.The exosome engineered targeted drug delivery system is prepared by mixing and reacting surface modified exosome and pH response type drug controlled release nanoparticles; the pH response type drug controlled release nanoparticles react with the surface modified exosome through a click chemical reaction; the surface of the membrane of which the surface is modified with the exosome is modified with a maleimide group and an azide group; the novel nano-drug has pH responsiveness; the click chemical reaction is thiol-ene click reaction. Bifunctional groups (MAL and N3) are directionally grafted on the surface of an exosome membrane, uniform drug particles are prepared in combination with a micro-fluidic technology, an efficient bimodal targeting drug delivery system is successfully constructed, and remarkable technical advantages are shown in the aspects of improving targeting precision, enhancing antitumor activity, controlling drug release, inhibiting tumor metastasis and the like; and a new technical approach is provided for precise treatment of adenoid cystic carcinoma.

The invention can provide compounds, analogs of blebbistatin, effective and selective inhibitors of nonmuscle myosin II relative to cardiac myosin II. Compounds can be used in the method of treating a disease, disorder, or medical condition in a patient, comprising modulating myosin II ATPase, such as treatment of substance abuse relapse disorder, or of renal disease, cancer and metastasis, benign prostate hyperplasia, hemostasis or thrombosis, nerve injury including retinal damage, lung fibrosis, liver fibrosis, arthrofibrosis, wound healing, spinal cord injury, periodontitis, glaucoma and immune-related diseases including multiple sclerosis; or wherein the disease, disorder, or medical condition comprises addiction including abuse of or addiction to anything classified as a Substance-Related or Addictive Disorder in the Diagnostic and Statistical Manual of Mental Disorders (DSM), such as, but not limited to, cocaine, opioids, amphetamines, ethanol, cannabis / marijuana, nicotine, and activities including gambling.Compounds are of general formulawith substituents as defined herein.

The invention discloses a colorectal cancer metabolism-related prognosis model construction method based on multiple omics. By integrating multiple omics data, the defect is overcome, a new view angle and method are provided, the accuracy and practicability of the prognosis model are effectively improved, and the blank in the prior art is filled. Meanwhile, the method provided by the invention is not only suitable for prognosis prediction of colorectal cancer patients, but also can be popularized and applied to other types of cancers. As the metabolism-related gene plays an important role in various cancers, the technical scheme provided by the invention has relatively high universality and popularization value, and can provide reference for prognosis prediction and personalized treatment of other cancers. Finally, the prognosis model provided by the invention can be used as a clinical decision support tool to help doctors to make more scientific and accurate decisions in diagnosis and treatment processes. Through early recognition of high-risk patients and implementation of targeted intervention measures, prognosis of the patients can be significantly improved, and the risk of relapse and metastasis can be reduced.

The invention belongs to the technical field of anti-tumor, and discloses application of HP and ICT combined anti-PD-1 inhibitor hydrogel in residual cancer recurrence after IRFA. The excellent drug delivery capacity of the hydrogel system is utilized, and the in-vivo local slow release effect of ICT and BMS202 can be remarkably amplified. Through synergistic treatment of the TAN and the MDSC, local and whole body adaptive immunoreactions can be efficiently activated, TAN is effectively reprogrammed to be in a tumor suppression type, infiltration of PMN-MDSC is reduced, and the conclusion is verified in a plurality of mouse tumor models in the chapter. Therefore, the HP (at) ICT / BMS provides a promising delivery strategy for improving the sensitivity of anti-PD-L1 treatment and efficiently preventing and treating latent residual cancer and metastasis after IRFA operation.

The invention belongs to the technical field of pharmaceutical preparations. The invention discloses a multifunctional bionic nano preparation, a preparation method and application. According to the multifunctional bionic nano preparation, the ginsenoside Rg3 has the dual functions of a medicine and a membrane stabilizer, the platelet membrane has the natural targeting capability on circulating tumor cells and metastases, and meanwhile, the cationic liposome is used for adsorbing negatively-charged NETs nucleic acid protein compounds, so that potential reversal and active targeting are achieved, and the multifunctional bionic nano preparation has a good application prospect. And by co-carrying paclitaxel (PTX) and a photothermal agent (PCP) and integrating photothermal-chemotherapy-immunogenic death (ICD) induction functions, the tumor-related fibroblast activation can be effectively inhibited, circulating tumor cells can be efficiently captured, a tumor immune microenvironment can be remodeled, the tumor cells can be effectively killed, and tumor distal metastasis can be inhibited.

The present application discloses a method of determining suitability of treating a patient suffering from cancer or metastasis of cancer characterized by aberrant expression of MUC1, with a MUC1* targeting therapeutic.

The invention relates to the field of biological medicine, and provides application of a biheterocyclic derivative in treating breast cancer and serving as an antitumor drug sensitizer. The invention discloses application of a biheterocyclic derivative in inhibiting proliferation of breast cancer cells, inhibiting formation, growth and metastasis of breast cancer tumors and enhancing chemosensitivity of the breast cancer cells and the tumors. It is found for the first time that the compound can inhibit proliferation of breast cancer cells at low concentration without affecting normal cells, and chemosensitivity of the breast cancer cells is improved. The formation and growth of breast cancer tumors can be obviously inhibited at the concentration without obvious organ toxicity, and the chemosensitivity of the breast cancer tumors is enhanced. According to the invention, the anticancer activity and the chemotherapy sensitization effect of the compound can be clarified, and a pharmaceutical basis is provided for drug development in the field of breast cancer treatment.

The invention provides a smearing sustained-release preparation and a preparation method and application thereof, the smearing sustained-release preparation comprises a chemotherapeutic drug component, an immune drug component and a sustained-release auxiliary material, and the smearing sustained-release preparation is in a transparent flowable sol shape. The sustained release preparation disclosed by the invention can be smeared and applied to a focus part in situ after a tumor operation. The application effect comprises the following steps: filling the treatment window period of the traditional postoperative adjuvant chemotherapy, and improving the local drug concentration of the focus through in-situ local slow release of the drug, thereby effectively removing residual tumor tissues and reducing the systemic toxicity of drug treatment; the metastasis and recurrence rate of tumors are further inhibited through the synergistic combined effect of chemotherapy-immune drugs in the preparation. The advantages show that the smearing sustained-release preparation provided by the invention has huge clinical potential in the aspect of tumor treatment.

The invention discloses a biomarker for predicting recurrence and metastasis risks of breast cancer and application of the biomarker. The invention discloses application of a substance for detecting a biomarker in preparation of a product for predicting the recurrence or metastasis risk of breast cancer. The biomarker comprises one or more of FBLN5, MUC16, ORM1, ADH1B, CD36, KRT19, DCD, DEFA3, RNASE1 and KLHL22. The invention further constructs a breast cancer recurrence or metastasis risk prediction model. According to the biomarker and the breast cancer recurrence or metastasis risk prediction model, the breast cancer recurrence or metastasis risk can be accurately, noninvasively and efficiently predicted, and clinical requirements can be met.

The present invention relates to the field of gene detection, and particularly to a primer-probe combination, a kit and their applications for detecting the benign and malignant nature of pulmonary nodules. The primer-probe combination includes primer pairs and probes for detecting gene mutation sites and methylation sites, and can achieve simultaneous detection covering the EGFR L858R mutation site, the EGFR 19Del mutation site, and the methylation sites of the HOXA7, CCNA1, and ZNF808 genes at one time. Thus, the present invention is a simple, rapid and accurate combined detection scheme for DNA methylation and gene mutation to assist in differentiating the benign and malignant nature of pulmonary nodules; at the same time, the primer-probe combination can achieve rapid pre-cancer screening, and also has application values such as accurate medication guidance and prognosis and metastasis risk prediction.

CD318 (CDCP1) is a CUB-domain containing cell surface protein over-expressed in major types of cancers to promote tumor growth and metastasis. The present disclosure relates to the identification and characterization of novel anti-CD318 monoclonal antibodies. By targeting CD318 as a tumor associated antigen, the disclosure further relates to different modalities of using anti-CD318 antibodies to kill cancer cells, including CD318 antibody based immunocytokines, CD318 antibody-based immune modulators, and CD318 antibody drug conjugates.

The invention discloses application of a small molecular compound secalonic acid B in inhibiting Skp2 protein and resisting prostate cancer cell metastasis, and belongs to the technical field of medicines. The research finds that secalonic acid B can obviously reduce the half-life period of Skp2, accelerate the degradation speed of Skp2 and reduce the protein level of Skp2 in DU145 cells by enhancing the polyubiquitination process on Skp2 protein. The secalonic acid B induces proteasome degradation of Skp2 through a multi-ubiquitination pathway of a K48 chain, so that tumor cell metastasis is inhibited, and the effect of resisting prostatic cancer is achieved. The invention discloses an action mechanism of secalonic acid B in inhibiting Skp2 protein and resisting prostate cancer cell metastasis, lays a theoretical foundation for research and development of drugs for inhibiting Skp2 protein and treating prostate cancer, and provides a new strategy for treatment of prostate cancer.

The invention relates to the field of disease risk prediction models, and discloses a thyroid cancer metastasis risk prediction model and a construction method and application thereof. The construction method of the model comprises the following steps: S1, collecting and preprocessing a sample; s2, gene expression quantity detection; s3, data set division and standardization processing; s4, constructing a deep learning model; s5, performing model evaluation; and the biomarker group for detecting the gene expression quantity in the S2 is composed of RPS4Y1, PKHD1L1, CRABP1, KRT18P8, AGPAT4, CPQ, SLC26A7 and RBP4. The prediction model can be used as a clinical auxiliary diagnosis tool and is used for guiding operation range selection, postoperative follow-up visit strategy making and early intervention of high-risk patients, and the precise diagnosis and treatment level of thyroid cancer is improved.

The invention discloses a method for promoting renal clear cell carcinoma metastasis by VSIG4 through epithelial-mesenchymal transition, which comprises the following steps: S1, clinical data analysis of ccRCC patients: S1.1, data collection: collecting clinical data of ccRCC patients, including two groups of primary metastatic-free tumor patients and metastatic patients, and observing whether there is statistical difference in expression of VSIG4 on renal carcinoma pathological tissues of the two groups of patients; s1.2, immunohistochemical staining and scoring: performing VSIG4 immunohistochemical staining and scoring on pathological section tissues of the ccRCC patients, grouping according to whether the VSIG4 is highly expressed, and observing whether the patients have disease imaging progression and whether the total lifetime is different; and S1.3, expression difference research: determining the effect of the VSIG4 in invasion and metastasis of the kidney cancer according to the expression difference of the VSIG4 among the kidney cancer, the para-carcinoma and the cancerous pseudoenvelop. According to the application disclosed by the invention, the VSIG4 promotes the metastasis of the renal clear cell carcinoma through epithelial-mesenchymal transition, and a potential means is provided for treating metastatic renal carcinoma by taking the VSIG4 as a target.

The embodiment of the invention provides a method and device for identifying lymph node metastasis and prognosis prediction under non-small cell lung cancer carina based on dual-region radiomics and a deep learning model, a storage medium and electronic equipment, and relates to the technical field of lung cancer diagnosis. Compared with a traditional scheme for judging lymph node metastasis of a non-small cell lung cancer patient based on physician experience, an artificial intelligence model is constructed by using dual-region CT radiomics, and a highly reliable prediction result is obtained.

The invention relates to the technical field of hyperspectral image processing, and particularly discloses a tumor classification method and system based on a tumor hyperspectral image, which can provide richer and more meticulous tumor tissue feature information including spectral features, morphological features, metabolic features and the like through a multiband reflection spectral image acquired by hyperspectral imaging equipment. The comprehensive information acquisition is helpful for doctors and researchers to comprehensively understand the characteristics of tumor tissues, and an important basis is provided for accurate diagnosis and personalized treatment. The invasiveness is one of the important indexes of the tumor malignancy degree, and knowing the invasiveness characteristics of the tumor tissue is beneficial to evaluating the growth and diffusion capabilities of the tumor tissue, so that important reference is provided for formulating a treatment scheme and predicting the prognosis of a patient. Meanwhile, the dynamic influence of spatial distribution on the tumor tissue metastasis capacity is quantified, and the metastasis potential of the tumor tissue can be evaluated more accurately. Doctors can be helped to formulate a treatment scheme better, the transfer process is intervened in time, and the treatment effect and the survival rate are improved.

The invention belongs to the technical field of biological medicine and molecular biology, and relates to application of TRIM38 as a therapeutic target and a prognostic marker of breast cancer. Research accidentally finds that TRIM38 can inhibit proliferation and metastasis of breast cancer, and further research shows that TRIM38 can block autophagy flow of breast cancer cells. Meanwhile, the TRIM38 can have a combined anti-tumor effect with autophagy inhibitors such as hydroxychloroquine and the like. In addition, the research shows that the TRIM38 can also be used as a prognostic marker of a breast cancer patient.

The invention discloses application of Bombyx mori neuropeptide BommoOKAtype4 in preparation of a medicine for inhibiting melanoma cell growth, and belongs to the technical field of medical biology. Aiming at the technical problems that melanoma is high in malignancy degree, easy to transfer and limited in treatment means, and whether the bombyx mori neuropeptide BommoOKAtype4 can directly inhibit the growth of melanoma cells is not clear yet when the bombyx mori neuropeptide BommoOKAtype4 is mainly used for skin whitening before, the invention provides the application of the bombyx mori neuropeptide in preparing the medicine for inhibiting the melanoma cells. According to the silkworm neuropeptide, gene expression and protein functions of melanin synthesis key enzymes TYR, TRP1 and TRP2 are comprehensively inhibited by down-regulating expression of a core transcription factor MITF, so that melanoma cell proliferation is directly inhibited while melanin synthesis is inhibited, and therefore, the silkworm neuropeptide can be used for preparing drugs for treating melanoma and has a wide application prospect. A novel peptide candidate substance is provided for treatment of melanoma.

The invention belongs to the field of medicines, and particularly relates to a nanosheet capable of activating an STING pathway and improving microwave ablation as well as a preparation method and application of the nanosheet. The nanosheet is prepared from MXenes through organic acid treatment, organic alkali dispersion, STING agonist compounding and phospholipid modification, and has good microwave thermal conversion efficiency and an STING pathway activation function. The combined microwave ablation can enhance the immunogenic death of tumor cells, promote the maturation of dendritic cells, doubly activate immune response and effectively inhibit the growth and metastasis of prostatic cancer, provides a new strategy for the treatment of prostatic cancer, and can be used for preparing drugs for treating prostatic cancer.

Provided are compositions that include a histone deacetylase inhibitor (HDACi) encapsulated in and / or otherwise associated with a nanoparticle. In some embodiments, the HDACi is romidepsin, vorinostat, belinostat, panobinostat, and / or chidamide. In some embodiments, the nanoparticle is a poly(D,L-lactide)-PEG-methyl ether (mPEG-PDLLA) nanopolymer. Also provided are methods for treating diseases, disorders, and / or conditions associated with sensitivity to histone deacetylase inhibitors, such as but not limited to tumors and / or cancers; and methods for inhibiting the growth, proliferation, and / or metastasis of a tumor and / or a cancer associated with sensitivity to histone deacetylase inhibitors by administering an effective amount of a composition as disclosed herein, which methods can optionally include administering at least one additional therapeutically active agent, such as but not limited to a chemotherapeutic agent.

The invention belongs to the technical field of biological medicine, and particularly relates to a reagent for detecting glycosylation modified RNA and application of the reagent in lung cancer metastasis prediction. According to the invention, glycosylation modification after RNA transcription is associated with the important pathological process of lung cancer metastasis for the first time, and a new theoretical basis and target are provided for diagnosis and treatment of lung cancer metastasis. In the prior art, the expression levels of genes and proteins are mainly concerned, and the invention goes deep into the RNA modification level and provides deeper and more accurate molecular information. And secondly, by detecting the glycosylation modification level of the LADENI, not only the expression quantity of the LADENI, the specificity and sensitivity of the LADENI as a biomarker are improved. The modification is dynamic and closely related to the function, so that the metastasis potential of the tumor cells can be reflected more accurately.

The present invention relates to a composition for preventing, alleviating or treating liver cancer, containing, as an active ingredient, a Melosila nummuloides extract, and, more specifically, to an excellent cell death and metastasis inhibitory effect of a Melosila nummuloides extract on liver cancer cells, the Melosila nummuloides extract being extracted using a mixed solvent of chloroform and methanol.